KR102518451B1 - Peg화된 돼지 인터페론 및 그의 사용 방법 - Google Patents

Peg화된 돼지 인터페론 및 그의 사용 방법 Download PDF

Info

Publication number
KR102518451B1
KR102518451B1 KR1020227019809A KR20227019809A KR102518451B1 KR 102518451 B1 KR102518451 B1 KR 102518451B1 KR 1020227019809 A KR1020227019809 A KR 1020227019809A KR 20227019809 A KR20227019809 A KR 20227019809A KR 102518451 B1 KR102518451 B1 KR 102518451B1
Authority
KR
South Korea
Prior art keywords
leu
arg
gln
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227019809A
Other languages
English (en)
Korean (ko)
Other versions
KR20220086700A (ko
Inventor
피터 코너 캐닝
니콜라스 크누센
릴리안 스키드모어
Original Assignee
엘랑코 유에스 인코포레이티드
암브룩스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘랑코 유에스 인코포레이티드, 암브룩스, 인코포레이티드 filed Critical 엘랑코 유에스 인코포레이티드
Publication of KR20220086700A publication Critical patent/KR20220086700A/ko
Application granted granted Critical
Publication of KR102518451B1 publication Critical patent/KR102518451B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227019809A 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법 Active KR102518451B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662352163P 2016-06-20 2016-06-20
US62/352,163 2016-06-20
KR1020187036853A KR102409470B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법
PCT/US2017/037964 WO2017222940A1 (en) 2016-06-20 2017-06-16 Pegylated porcine interferon and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036853A Division KR102409470B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법

Publications (2)

Publication Number Publication Date
KR20220086700A KR20220086700A (ko) 2022-06-23
KR102518451B1 true KR102518451B1 (ko) 2023-04-04

Family

ID=59258379

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227019809A Active KR102518451B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법
KR1020187036853A Active KR102409470B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187036853A Active KR102409470B1 (ko) 2016-06-20 2017-06-16 Peg화된 돼지 인터페론 및 그의 사용 방법

Country Status (18)

Country Link
US (2) US10960080B2 (https=)
EP (1) EP3471755B1 (https=)
JP (2) JP7093311B2 (https=)
KR (2) KR102518451B1 (https=)
CN (2) CN117024562A (https=)
AU (2) AU2017280958A1 (https=)
BR (1) BR112018076437A2 (https=)
CA (1) CA3028683A1 (https=)
CL (1) CL2018003697A1 (https=)
DK (1) DK3471755T3 (https=)
EA (1) EA036509B1 (https=)
ES (1) ES2793773T3 (https=)
MX (1) MX391970B (https=)
NZ (1) NZ749962A (https=)
PL (1) PL3471755T3 (https=)
PT (1) PT3471755T (https=)
WO (1) WO2017222940A1 (https=)
ZA (1) ZA201808352B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
CN113845599B (zh) * 2021-11-01 2023-09-19 长春萤火虫生物科技有限公司 一种重组猪干扰素融合蛋白及其应用
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070237743A1 (en) 2005-06-20 2007-10-11 Villarete Lorelie H Combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
US20080132681A1 (en) 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
CN104262480A (zh) 2014-09-28 2015-01-07 重庆理工大学 重组猪长效-α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
JP2006213597A (ja) * 2000-07-19 2006-08-17 Pepgen Corp インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
CN101883784B (zh) 2007-10-01 2014-10-15 药华医药股份有限公司 N-端修饰的干扰素-α
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080132681A1 (en) 2005-06-03 2008-06-05 Ambrx, Inc. Human Interferon Molecules and Their Uses
US20070237743A1 (en) 2005-06-20 2007-10-11 Villarete Lorelie H Combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN104262480A (zh) 2014-09-28 2015-01-07 重庆理工大学 重组猪长效-α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Also Published As

Publication number Publication date
EP3471755A1 (en) 2019-04-24
DK3471755T3 (da) 2020-05-18
JP7093311B2 (ja) 2022-06-29
EA036509B1 (ru) 2020-11-18
KR20190039889A (ko) 2019-04-16
KR102409470B1 (ko) 2022-06-16
CA3028683A1 (en) 2017-12-28
ZA201808352B (en) 2020-08-26
EA201892671A1 (ru) 2019-05-31
MX2018016295A (es) 2019-09-16
AU2021229132B2 (en) 2023-04-06
EP3471755B1 (en) 2020-04-22
AU2017280958A1 (en) 2018-12-20
CL2018003697A1 (es) 2019-05-10
JP2019519553A (ja) 2019-07-11
US10960080B2 (en) 2021-03-30
CN109641034B (zh) 2023-08-15
PT3471755T (pt) 2020-05-22
CN117024562A (zh) 2023-11-10
BR112018076437A2 (pt) 2019-10-01
MX391970B (es) 2025-03-21
WO2017222940A1 (en) 2017-12-28
CN109641034A (zh) 2019-04-16
NZ749962A (en) 2020-06-26
US20210177980A1 (en) 2021-06-17
PL3471755T3 (pl) 2020-10-19
AU2021229132A1 (en) 2021-09-30
KR20220086700A (ko) 2022-06-23
JP7441892B2 (ja) 2024-03-01
ES2793773T3 (es) 2020-11-16
US20190192673A1 (en) 2019-06-27
JP2022137063A (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
KR102518451B1 (ko) Peg화된 돼지 인터페론 및 그의 사용 방법
US12269856B2 (en) Hepcidin analogues and uses thereof
KR20090089316A (ko) Ｐｅｇ 변형된 엑센딘 또는 엑센딘 유사체 및 조성물 및 이의 용도
EP2853536B1 (en) Long-acting erythropoietin polypeptides and uses thereof
KR20230053615A (ko) 접합된 헵시딘 모방체
US11530249B2 (en) Long-acting conjugates of GLP-2 derivatives
US20040142866A1 (en) Derivatives of the insulinotropic peptide exendin-4 and methods of production thereof
KR20180014754A (ko) 페길화된 옥신토모둘린 변이체
KR20220125289A (ko) Fgf-21 접합체 제제
CN101671390B (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
US20240052330A1 (en) Blockade of sars-cov-2 infection using hydrocarbon stapled peptides
DK2618830T3 (en) Formulations to a kvæggranulocytkolonistimulerende factor and variants thereof
WO2026055636A1 (en) Peptides and compositions for improving glucose levels
HK40084564A (en) Hepcidin analogues and uses thereof
CN101385858A (zh) 纯化的peg化人生长激素缀合物及其药物制剂
NZ751741B2 (en) Hepcidin analogues and uses therof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220610

Application number text: 1020187036853

Filing date: 20181219

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220707

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220718

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230104

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230331

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230331

End annual number: 3

Start annual number: 1

PG1601 Publication of registration